Purpose: To examine the seizure-protective properties of fluorofelbamate, a felbamate analog, on acute and chronic seizures in an experimental model of self-sustaining status epilepticus (SSSE).
INTRODUCTION
Felbamate, an anticonvulsant active at NMDA receptors [1] [2] [3] [4] [5] , which is also a potent neuroprotective agent [6] [7] [8] [9] [10] [11] , was shown to be effective in treating refractory seizures in humans 12, 13 and self-sustaining status epilepticus (SSSE) in experimental animals 14 . However, its use has been curtailed by hematological and hepatic toxicity during chronic use 15 . The present hypothesis for adverse reactions associated with the use of felbamate is attributed to the formation of a reactive aldehyde (atropaldehyde or 2-phenylpropenol) intermediate that interacts with proteins 16, 17 . The new felbamate analog, fluorofelbamate ( Fig. 1) does not undergo the formation of this reactive aldehyde in its metabolism. The protective mechanism whereby the liver detoxifies this reactive metabolite is via the formation of a glutathione conjugate using glutathione transferase 18 . Moreover, fluorofelbamate has a similar anticonvulsant profile but in some cases is more potent than felbamate in animal seizure models. For instance, the ED50 in maximal electroconvulsive seizures for felbamate and fluorofelbamate in rats following oral administration is 25 and 3 mg kg −1 , respectively 19 . In preliminary experiments the glutathione-aldehyde adduct that can be found in the urine of rats and humans following administration of felbamate 20 was not observed in rats treated with fluorofelbamate (unpublished data).
Our previous studies showed that application of 30 min perforant path stimulation (PPS) to free running rat results in the development of longlasting seizures (up to 24 h) which no longer depend on continuing stimulation, i.e. SSSE 21 . In turn, SSSE is accompanied by extensive neuronal injury to the hippocampus and extrahippocampal areas, mossy fiber sprouting, and chronic epilepsy with recurrent spontaneous seizures 21, 22 . In addition, SSSE showed a distinct pharmacological profile: conventional antiepileptic drugs (diazepam, phenytoin) showed a decline in anticonvulsant effects with increasing duration of SSSE 21 ; NMDA receptor blockers (ketamine, MK-801) induced irreversible block of SSSE; the AMPA-kainate receptor antagonist CNQX induced short-lasting reversible suppression of seizures 23 . Finally, felbamate induced dose-dependent irreversible suppression of SSSE 14 .
We examined the anticonvulsant properties of FFBM in the rat model of SSSE in order to determine whether it shares the therapeutic effectiveness of its parent compound in this model. In addition, we studied the effect of acute treatment of SSSE with FFBM on the course of the chronic epilepsy, which evolves after SSSE 22 .
METHODS

Animals
The experiments were performed on male Wistar rats (Simonsen Laboratories, Gilroy, CA), weighing 260-280 g. The animals were housed individually with 12 h light-dark cycle, and food and water ad libitum. Experimental procedures were done in accordance with the requirements of the Animal Research Committee of the West Los Angeles VA Medical Center and the University of California.
Surgery
Under ketamine (60 mg kg −1 ) and xylazine (15 mg kg −1 ) anesthesia, the animals were implanted with a bipolar stimulating electrode into the angular bundle of the perforant path (0.5 mm anterior and 4.5 mm left to lambda) and a bipolar recording electrode into the ipsilateral dentate gyrus (3 mm posterior and 2.5 mm left to bregma). The depth of the electrodes (Plastics One Roanoke, VA) was 3.5-4 mm from the brain surface and was optimized by finding the maximal population spike evoked from the dentate gyrus (recorded by means of personal computer equipped with rapid systems scope software) by square wave monophasic stimuli (0.1 Hz, 30 V, 0.1 ms duration delivered by Grass 8800 stimulator) applied to the perforant path. The postoperative recovery period was 7-10 days.
Induction of SSSE and administration of FFBM SSSE was induced as described earlier 14, 21 . Briefly, PPS was delivered for 30 min to free-running rats using a Grass 8800 stimulator with the following parameters: 10 s 20 Hz trains of 1 ms 30 V pulses delivered every minute, together with continuous 2 Hz stimulation with the same parameters. Electrical activity during and after PPS was recorded from the dentate gyrus by means of Harmonie software (Stellate systems, Montreal, Quebec), configured for automatic detection and saving of seizure and spike events.
FFBM in 10% DMSO was injected into the tail vein (i.v.) of temporarily immobilized animals (using plastic restrictive cones, Harvard Apparatus, USA) in doses of 50, 100, or 200 10 min after PPS, during the early phase of SSSE, or on doses of 200 or 300 mg kg −1 40 min after the end of PPS, when SSSE is more resistant to pharmacological manipulations 21 . Control animals were treated with 10% DMSO.
No mortality was observed in any experimental group.
Seizure monitoring and quantification
During SSSE, the number of electrographic seizures, the time of the occurrence of the last seizure, and the number of spikes for 1 h epoch were counted as described earlier 14, 21 .
After SSSE control animals, or animals treated with FFBM, 200 mg kg −1 were placed for chronic electrographic and video monitoring. Electrographic seizures and spikes were captured by the Harmonie software, and were confirmed by offline review of the videotapes. The following indices were counted: time between PPS and first, fifth and 10th seizures; number of seizures on days 1, 10 and 30 (day 1 was the day when the first seizure occurred and therefore was different for each animal); and total number of seizures displayed between days 20-30, 40-50 and 60-70. In addition, frequency of interictal spikes was analyzed as follows. In seven control and five FFBM treated rats selected randomly, random 4 h epochs were selected on the first, 1, 3, 5 and 15 days after PPS, before the occurrence of 1st spontaneous seizure, and on the days 1, 15, 20 and 27 after the occurrence of the first spontaneous seizure. Spike frequency was counted during these 4 h epochs, and then the mean ± SEM spike frequency was calculated for each of the animals for the two conditions: before (silent period), and after the occurrence of the first seizure. Data were analyzed using where appropriate oneway ANOVA followed by Newman-Keuls post hoc test or, if the normality test failed, by ANOVA on ranks followed by a Mann-Whitney post hoc test.
RESULTS
Thirty minute PPS induced SSSE in all animals, with recurring behavioral and electrographic (Fig. 2) seizures lasting many hours in untreated rats (Fig. 3) . Behavioral limbic-like seizures (with rearing and/or falling) were accompanied electrographically by high-frequency spikes (Fig. 2) . Between seizures, animals continued to display less severe convulsive behavior (motor arrest, myofacial clonus) accompanied by electrographic spikes or spike-and-wave complexes (Fig. 2) . Behavioral and electrographic seizures continued for 8-24 h after the end of PPS. In untreated rats, the mean ± SEM time spent actively seizing was 392 ± 11 min, and the mean ± SEM duration of SSSE was 756 ± 33 min.
Effects of FFBM treatment on behavior
Administration of FFBM in doses of 50 and 100 mg kg −1 did not result in any visible behavioral changes. After injection of 200 mg kg −1 animals showed ataxia and muscle relaxation, which lasted for 10-25 min. Similar signs, lasting 10-35 min, were observed after a dose of 300 mg kg −1 . Corneal and tail-pinch reflexes were preserved in all treatment groups.
Effects of FFBM treatment on SSSE
Administration of FFBM 10 min after the end of PPS resulted in a dose-dependent attenuation of SSSE (Figs 2 and 3) . FFBM injected at a dose of 50 mg kg −1 did not affect seizure severity and duration. Seizures stopped after 15 ± 8 min following administration of 100 mg kg −1 of FFBM, and after 2.4 ± 0.5 min after 200 mg kg −1 , and the duration of status was 79 ± 43 and 6.8 ± 1.7 min, respectively. This compares to a seizure duration of 393 ± 10 min and a status duration of 756 ± 32 min in controls. Electrographic spikes were significantly suppressed after FFBM treatment in doses of 100 and 200 mg kg −1 (Fig. 3(b) ). Mean ± SEM spike frequency was 150 ± 19 per hour after 100 mg kg −1 FFBM, and 30 ± 12 after 200 mg kg −1 , which was significantly less than in rats untreated (532 ± 55) or treated with FFBM, 50 mg kg −1 (446 ± 50). Lower-dose FFBM (50 mg kg −1 in 2 rats and 100 mg kg −1 in 3 rats) did not attenuate SSSE when injected 40 min after 30 min PPS (data not shown). However, in doses of both 200 and 300 mg kg −1 , late injection of FFBM significantly attenuated SSSE severity and duration (209 ± 55 and 76 ± 11 min respectively, Fig. 4(a) ). The frequency of spikes during SSSE was not affected by late treatment (Fig. 4(b) ).
Effects of treatment on chronic epilepsy
We next examined whether effective treatment of SSSE with FFBM (200 mg kg −1 injected 10 min after PPS) affected the course of delayed chronic epilepsy. The duration of the 'silent' period (time between SSSE and the first seizure) did not differ between the control and FFBM-treated groups (Fig. 5(a) ). However, the progression of chronic epilepsy was slower in FFBM-treated rats, which took 40 ± 1 days to develop five spontaneous stage 5 seizures vs. 29 ± 2 days in the control group. Frequency of spontaneous seizures was also lower in FFBM-treated animals: none of the animals averaged more than one seizure per day, whereas in the untreated control group, daily seizure frequency was 6 − 1 ( Fig. 5(b) ). Furthermore, frequency of spontaneous seizures decreased over time in FFBM-treated rats, and no seizures were recorded more than 2 months after SSSE, while seizure frequency remained unchanged in untreated rats. Seizure frequency averaged 4.6 + 1.5 per day in a group of five control rats, recorded 6-13 months after SSSE, while none of five FFBM-treated animals showed any spontaneous seizures when observed between 7 and 12 months after SSSE (Fig. 5(b) ). Because recordings were limited in time (usually to a continuous period of 7 days), we cannot rule out the occurrence of infrequent seizures in some animals in the FFBM group, although none occurred during the recordings.
In addition, FFBM treatment significantly decreased the frequency of interictal spikes. While in the untreated control group interictal spikes were observed starting the day after SSSE, and their frequency was steady throughout the silent period and after the occurrence of the first spontaneous seizure, this parameter was 6-7 fold lower in FFBM-treated rats (Fig. 5(c) ).
DISCUSSION
Status epilepticus remains a difficult management problem, with a mortality of 27% and high morbidity 24, 25 , and little information is available to differentiate the acute effects of various therapeutic agents on mortality and morbidity, or to predict the effects of treatment on the long-term consequences of status epilepticus.
The only controlled study comparing therapeutic regiments in human status epilepticus used only traditional drugs 26 , and found little difference between them in efficacy.
In this study, we used a model of self-staining status epilepticus induced by a brief intermittent electrical stimulation of the perforant path in free-moving rats. This model has the advantage of testing SSSE in the absence of chemical toxins, so that complications can be ascribed to seizures per se.
In most clinical situations, treatment is rarely available in the field, and transportation takes time, so that status epilepticus must be treated after seizures have been ongoing for many minutes to hours 27 . Studies conducted in experimental animals have shown a progressive decrease in responsiveness of hippocampal neurons to benzodiazepines and other GABAergic drugs 28 , and a progressive loss of therapeutic effectiveness of those drugs 21 with increasing seizure duration. Our studies showed, that diazepam and phenytoin were both quite effective when given early in the current study, confirming previous results, but failed to abort SSSE when administered after 40 or 70 min after the onset of stimulation (failure was defined as continued seizures lasting over 30 min) 21 . In contrast, FFBM effectively blocked SSSE when injected at both its early and advanced stages. Its action was definitive: we saw no late return of seizure activity such as seen with diazepam, or non-NMDA glutamate receptor blockers 21, 23 . We previously showed that in this model, NMDA receptor blockers were highly successful in stopping established SSSE, even in its advanced stages 23 . We do not know whether FFBM shares that NMDA receptor-blocking properties of its parent compound felbamate, but if it should, this might explain its effectiveness in the current study.
The effect of FFBM was dose dependent, and a high dose of anticonvulsant was required to abort SSSE. This is not surprising, since SE requires more vigorous treatment than single seizures, and this has been observed with many therapeutic agents. Little information is available on the effect of acute treatment of status epilepticus on its epiletogenicity. Experimental evidence indicates that seizure-induced epiletogenicity is a widespread and common phenomenon; chronic epilepsy develops after a latent period in the majority of animals in which status epilepticus was induced by electrical stimulation, kainic acid, or pilocarpine 22, [29] [30] [31] [32] . However, we do not know whether treatment of status epilepticus prevents the development of chronic epilepsy, or whether the timing of treatment, its intensity and the nature of the therapeutic agent influence outcome. In previous studies, we found that treatments that terminate SE after 20 min of PPS prevented epileptogenesis, and that a number of anticonvulsants were equally affective in that respect 22 . In the current investigation, treatment of SSSE with FFBM attenuated chronic epilepsy. Such treatment reduced neither the initial incidence of spontaneous seizures, nor the duration of silent period, but it reduced frequency and severity of seizures, and the evolution of the chronic epilepsy seemed altered. The frequency of spontaneous seizures decreased with time in the FFBM group, while remaining constant in controls. The complete absence of seizures during videotelemetry recording lasting from 9 to 20 days in six animals observed 6-13 months after the episode of status, does not completely rule out the possibility that rare seizures may have occurred, especially since most of the rats still showed some interictal spikes. However, the striking difference between that result and the continued high incidence of spontaneous seizures in controls (averaging five seizures a day) suggests that the acute treatment of SSSE with FFBM has both anticonvulsant and anti-epileptogenic effects.
In conclusion, the combination of high efficacy against SSSE and low acute toxicity suggests that FFBM may deserve evaluation for the treatment of status epilepticus.
